Literature DB >> 15373940

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics.

Margit Fröhlich, Michael M Hoffmann, Jürgen Burhenne, Gerd Mikus, Johanna Weiss, Walter E Haefeli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15373940      PMCID： PMC1884607          DOI： 10.1111/j.1365-2125.2004.02159.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry.

Authors:  Jürgen Burhenne; Klaus Dieter Riedel; Meret Martin-Facklam; Gerd Mikus; Walter E Haefeli
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-02-05       Impact factor: 3.205

Review 3.  Genetic contribution to variable human CYP3A-mediated metabolism.

Authors:  Jatinder K Lamba; Yvonne S Lin; Erin G Schuetz; Kenneth E Thummel
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

4.  The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

Authors:  J T Backman; K T Kivistö; K T Olkkola; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1998-03       Impact factor: 2.953

Review 5.  Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.

Authors:  D P Figgitt; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

6.  Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction.

Authors:  Gerd Mikus; Laila Schmidt; Jürgen Burhenne; Reinhard Ding; Klaus-Dieter Riedel; Yorki Tayrouz; Johanna Weiss; Walter Emil Haefeli
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.

Authors:  Meret Martin-Facklam; Jürgen Burhenne; Reinhard Ding; Ruth Fricker; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

8.  Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.

Authors:  M E Fitzsimmons; J M Collins
Journal:  Drug Metab Dispos       Date:  1997-02       Impact factor: 3.922

9.  Oral contraception does not alter single dose saquinavir pharmacokinetics in women.

Authors:  Margit Fröhlich; Jürgen Burhenne; Meret Martin-Facklam; Johanna Weiss; Michael von Wolff; Thomas Strowitzki; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

10.  In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

Authors:  Kiran C Patki; Lisa L Von Moltke; David J Greenblatt
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922
View more
  13 in total

1.  PharmGKB summary: very important pharmacogene information for CYP3A5.

Authors:  Jatinder Lamba; Joan M Hebert; Erin G Schuetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

2.  The impact of host pharmacogenetics on antiretroviral drug disposition.

Authors:  Andrew Owen
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

Review 3.  Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

Authors:  Margalida Rotger; Chantal Csajka; Amalio Telenti
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

4.  An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat.

Authors:  Brendan T Griffin; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2007-11-02       Impact factor: 4.200

5.  The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.

Authors:  Patrick J Roberts; Kristan D Rollins; Angela D M Kashuba; Mary F Paine; Andrew C Nelsen; Eric E Williams; Cassandra Moran; Jatinder K Lamba; Erin G Schuetz; Roy L Hawke
Journal:  Drug Metab Dispos       Date:  2008-05-19       Impact factor: 3.922

6.  Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).

Authors:  Jose R Castillo-Mancilla; Christina L Aquilante; Michael F Wempe; Laura M Smeaton; Cynthia Firnhaber; Alberto M LaRosa; Nagalingeswaran Kumarasamy; Adriana Andrade; Gautam Baheti; Courtney V Fletcher; Thomas B Campbell; David W Haas; Samantha MaWhinney; Peter L Anderson
Journal:  J Antimicrob Chemother       Date:  2016-02-17       Impact factor: 5.790

7.  The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

Authors:  Samir K Gupta; Susan L Rosenkranz; Yoninah S Cramer; Susan L Koletar; Lynda A Szczech; Valerianna Amorosa; Stephen D Hall
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

8.  Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.

Authors:  Peter L Anderson; Christina L Aquilante; Edward M Gardner; Julie Predhomme; Patrick McDaneld; Lane R Bushman; Jia-Hua Zheng; Michelle Ray; Samantha MaWhinney
Journal:  J Antimicrob Chemother       Date:  2009-08-26       Impact factor: 5.790

Review 9.  CYP3A5 polymorphism, amlodipine and hypertension.

Authors:  Y-P Zhang; X-C Zuo; Z-J Huang; J-J Cai; J Wen; D D Duan; H Yuan
Journal:  J Hum Hypertens       Date:  2013-07-18       Impact factor: 3.012

10.  Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.

Authors:  Caroline Solas; Nicolas Simon; Marie-Pierre Drogoul; Sylvie Quaranta; Véronique Frixon-Marin; Véronique Bourgarel-Rey; Corinne Brunet; Jean-Albert Gastaut; Alain Durand; Bruno Lacarelle; Isabelle Poizot-Martin
Journal:  Br J Clin Pharmacol       Date:  2007-05-22       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.